Alliance Pharma Share Discussion Threads

[bones698] 08/5/2024 17:00

This is risky while the bid are making changes and no reuslts published. Is it there is something nasty lurking, I have seen this before so wouldn't want to be holding shares at this time until things become clear,simply not worth the risk.

I'll keep it on my watch list but expect this to continue to fall until we see the results and what's going on

[tomzimerman] 08/5/2024 16:53

Very true, I've said many times theres better opportunities but maybe the lows today were an opportunity, I don't and have never looked deep enough, just stating to others to ignore constant spam posting and Dyor etc etc etc. say it again, hopefully this turns around for genuine people

[blackhorse23] 08/5/2024 16:52

Lucky who bought at dip

[justiceforthemany] 08/5/2024 16:26

Is it?
Wild speculation.
It could just as easily receive another takeover offer (or two) here sat at 2012 lows.

[simon gordon] 08/5/2024 15:31

FT - 8/5/24:

Sedgwick will have to turn around flagging performance at the company. In an unaudited trading update in January, Alliance cut its profit expectations for 2024 to 18 per cent below analyst estimates, saying that it would need to expand investments in sales and marketing to increase revenues, which were £182.7mn in 2023.

The business has spent £380mn on acquisitions since it listed in 2003, according to Jantet, buying up old medicine brands that it then tried to turn around. This increased debt levels to 2.7x earnings in 2022, although analysts anticipate this level will have fallen in the 2023 results and Jantet said current debt levels were not “concerning221;.

Despite its outlay on new products, few have proved successful, said Miles Dixon, an analyst at Peel Hunt. Scar treatment Kelo-Cote accounted for more than a third of total revenue, according to the January update, in a portfolio of about 80 brands.

“If Kelo-Cote slows down, it’s the only growth product. If they were to refinance debt, it’d be expensive,” Dixon added.

The share price fall on Wednesday brings the total decline in the past year to 62.5 per cent, hitting the company’s many UK investors.

“It’s traditionally been a story that’s popular with UK fund managers. It’s easy to explain, traditionally pays a dividend, and has lots of analyst coverage,” Dixon said. “It’s an indictment of UK thinking to stick with something like this rather than look at more specialist healthcare stories,” such as high-growth biotech companies.

=====

The Amberen deal at $110m was horrific and collapsed the share price. Is the market pricing in a rights issue to strengthen the balance sheet?

[justiceforthemany] 08/5/2024 15:15

Be greedy when others are fearful?
Pharmaceutical company trading at 6x earnings and half NAV?
(Unless KPMG and Deloitte have both been signing off completely bogus accounts for the last decade).

[tomzimerman] 08/5/2024 13:33

You still buying more ffs sheeesh tr1 coming???

[blackhorse23] 08/5/2024 13:15

Account will be publishing anyway & it will be accurate as mentioned 29th January , so all good

[seagreen] 08/5/2024 13:02

I could buy a bottle of cheap plonk to but wil wait for the chateau du chasseur *-)

[baldrick1] 08/5/2024 12:51

I could make money buying in at 25.65p and selling at 27.50p

[buoycat] 08/5/2024 12:30

Likely to end in tears. been in these situations before, there's no smoke without fire. It's a massive risk buying now, when clearly there's a problem here.

[blackhorse23] 08/5/2024 12:29

Give us an opportunity to buy tbh

[blackhorse23] 08/5/2024 12:17

Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations.

[blackhorse23] 08/5/2024 12:16

Once published accounts it will be boom , matter of time now

[justiceforthemany] 08/5/2024 12:09

If the accounts are to be believed current assets are almost 2x current liabilities and the shares are now trading at half their book value.

[nakedmolerat] 08/5/2024 11:16

points and laughs at blacknag

[justiceforthemany] 08/5/2024 11:12

RSI just 7.
Wow.
Are APH going into mining?

[peddlers] 08/5/2024 10:45

Imagine buying this for an additional 10% loss today 🙈.
Some folk will never learn.

I sold at 36.5p for a loss last month.
I should have pivoted and went short.

Terrible performance.

P

[baldrick1] 08/5/2024 10:43

I'll buy back in at 18-20p

[lawson27] 08/5/2024 10:41

Do they have a cure for mange?

[mortimer7] 08/5/2024 10:39

When KPMG quit as Auditors in August 2022 their letter cited Corporate Governance issues. So Deloitte "won" the tender to become auditors & produced the 2022 figures - no surprise there.
However they've obviously now dug their heels in for 2023 results.
May be it's not a bad thing that these actions seem to be forcing things to come to a head. Possibly short term pain for long term gain?

[zipstuck] 08/5/2024 10:25

High Intangibles and Debt

[blackhorse23] 08/5/2024 10:22

Nick Sedgwick brings thirty years of consumer health experience across European, US and global roles at major multinational companies such as Reckitt, Coty and Nestlé. Most recently Nick was Regional Director for UK and Ireland Consumer Health at Reckitt during which time he increased revenue and improved profitability in the second largest market for the company. Prior to this, Nick worked at Coty holding a number of senior roles including Senior Vice President for Global Sales and Commercial Capabilities, Senior Vice President Sales for the US business and General Manager Consumer Beauty for UK and Ireland. Throughout his career, Nick has worked in multiple countries, always delivering high revenue growth through consumer-centric strategies, high performance teams and excellence in execution.

[blackhorse23] 08/5/2024 10:14

Bought more today